Overexpression of MDM2 in MCF-7 promotes both growth advantage and p53 accumulation in response to estradiol

Japanese Journal of Cancer Research

Volumn 90, Issue 2, 1999, Pages 210-218

  Saji, Shigehira ^a   Nakashima, Shigeru ^a   Hayashi, Shin Ichi ^b   Toi, Masakazu ^c   Saji, Shigetoyo ^a   Nozawa, Yoshinori ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

^c TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Breast cancer; Estrogen receptor; MDM2; p53

Indexed keywords

COMPLEMENTARY DNA; ESTRADIOL; ESTROGEN RECEPTOR; PROTEIN MDM2; PROTEIN P53;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CELL CYCLE; CELL STRAIN MCF 7; CONTROLLED STUDY; EXPRESSION VECTOR; HUMAN; HUMAN CELL; ONCOGENE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0032990481     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00735.x     Document Type: Article

References (49)

1. Cahilly-Snyder, L., Yang-Feng, T., Francke, U. and George, D. L. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat. Cell Mol. Genet., 13, 235-244 (1987).
2. Fakharzadeh, S. S., Trusko, S. P. and George, D. L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J., 10, 1565-1569 (1991).
3. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L. and Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 358, 80-83 (1992).
4. Momand, J., Zambetti, G. P., Olson, D. C., George, D. and Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237-1245 (1992).
5. Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J. and Pavletich, N. P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science, 274, 948-953 (1996).
6. Boddy, M. N., Freemont, P. S. and Borden, K. L. The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger. Trends Biochem. Sci., 19, 198-199 (1994).
7. Haupt, Y., Maya, R., Kazaz, A. and Oren, M. Mdm2 promotes the rapid degradation of p53. Nature, 387, 296-299 (1997).
8. Kubbutat, M. H., Jones, S. N. and Vousden, K. H. Regulation of p53 stability by Mdm2. Nature, 387, 299-303 (1997).
9. Barak, Y., Juven, T., Haffner, R. and Oren, M. mdm2 expression is induced by wild type p53 activity. EMBO J., 12, 461-468 (1993).
10. Xiao, Z. X., Chen, J., Levine, A. J., Modjtahedi, N., Xing, J., Sellers, W. R. and Livingston, D. M. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature, 375, 694-698 (1995).
11. Martin, K., Trouche, D., Hagemeier, C., Sorensen, T. S., LaThangue, N. B. and Kouzarides, T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature, 375, 691-694 (1995).
12. Marechal, V., Elenbaas, B., Piette, J., Nicolas, J. C. and Levine, A. J. The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol. Cell. Biol., 14, 7414-7420 (1994).
13. Elenbaas, B., Dobbelstein, M., Roth, J., Shenk, T. and Levine, A. J. The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol. Med., 2, 439-451 (1996).
14. Fiddler, T. A., Smith, L., Tapscott, S. J. and Thayer, M. J. Amplification of MDM2 inhibits MyoD-mediated myogenesis. Mol. Cell. Biol., 16, 5048-5057 (1996).
15. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell, 92, 713-723 (1998).
16. Zhang, Y., Xiong, Y. and Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92, 725-734 (1998).
17. Sigalas, I., Calvert, A. H., Anderson, J. J., Neal, D. E. and Lunec, J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat. Med., 2, 912-917 (1996).
18. Matsumoto, R., Tada, M., Nozaki, M., Zhang, C. L., Sawamura, Y. and Abe, H. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res., 58, 609-613 (1998).
19. Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M. R., Pollack, D., Woodruff, J. M., Marechal, V., Chen, J., Brennan, M. F. and Levine, A. J. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res., 54, 794-799 (1994).
20. McCann, A. H., Kirley, A., Carney, D. N., Corbally, N., Magee, H. M., Keating, G. and Dervan, P. A. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br. J. Cancer, 71, 981-985 (1995).
21. Quesnel, B., Preudhomme, C., Fournier, J., Fenaux, P. and Peyrat, J. P. MDM2 gene amplification in human breast cancer. Eur. J. Cancer, 30A, 982-984 (1994).
22. Inada, K., Toi, M., Yamamoto, Y., Suzuki, A., Kurisaki, T., Suzuki, H. and Tominaga, T. Immunocytochemical analysis of MDM2 protein expression and its relevance to tumor angiogenesis in primary breast cancer. Oncol. Rep., 3, 667-671 (1996).
23. Hideshima, T., Shinohara, T., Baba, M. and Shirakusa, T. The expression of MDM2 and p53 protein in breast carcinoma. Oncol. Rep., 4, 297-300 (1997).
24. Baunoch, D. A., Watkins, L. F., Tewari, A., Reece, M. T., Adams, L., Stack, R., Brown, A., Jones, L., Christian, D., Latif, N. A., Lawrence, W. D. and Lane, M. A. MDM2 overexpression in benign and malignant lesions of the human breast: association with ER expression. Int. J. Oncol., 8, 895-899 (1996).
25. Marchetti, A., Buttitta, F., Girlando, S., Dalla Palma, P., Pellegrini, S., Fina, P., Doglioni, C., Bevilacqua, G. and Barbareschi, M. mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J. Pathol., 175, 31-38 (1995).
26. Gudas, J. M., Nguyen, H., Kiein, R. C., Katayose, D., Seth, P. and Cowan, K. H. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clin. Cancer Res., 1, 71-80 (1995).
27. Roemer, K. and Friedmann, T. Modulation of cell proliferation and gene expression by a p53-estrogen receptor hybrid protein. Proc. Natl. Acad. Sci. USA, 90, 9252-9256 (1993).
28. Suzuki, A., Toi, M., Yamamoto, Y., Saji, S., Muta, M. and Tominaga, T. Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma. Jpn. J. Cancer Res., 89, 221-227 (1998).
29. Chen, L., Agrawal, S., Zhou, W., Zhang, R. and Chen, J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc. Natl. Acad. Sci. USA, 95, 195-200 (1998).
30. el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. and Vogelstein, B. WAFI, a potential mediator of p53 tumor suppression. Cell, 75, 817-825 (1993).
31. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. and Elledge, S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75, 805-816 (1993).
32. Dulic, V., Kaufmann, W. K., Wilson, S. J., Tlsty, T. D., Lees, E., Harper, J. W., Elledge, S. J. and Reed, S. I. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell, 76, 1013-1023 (1994).
33. Hurd, C., Khattree, N., Alban, P., Nag, K., Jhanwar, S. C., Dinda, S. and Moudgil, V. K. Hormonal regulation of the p53 tumor suppressor protein in T47D human breast carcinoma cell line. J. Biol. Chem., 270, 28507-28510 (1995).
34. Hurd, C., Khattree, N., Dinda, S., Alban, P. and Moudgil, V. K. Regulation of tumor suppressor proteins, p53 and retinoblastoma by estrogen and antiestrogens in breast cancer cells. Oncogene, 15, 991-995 (1997).
35. Yu, C. L., Driggers, P., Barrera-Hernandez, G., Nunez, S. B., Segars, J. H. and Cheng, S. The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways. Biochem. Biophys. Res. Commun., 239, 617-620 (1997).
36. Hall, P. A., McKee, P. H., Menage, H. D., Dover, R. and Lane, D. P. High levels of p53 protein in UV-irradiated normal human skin. Oncogene, 8, 203-207 (1993).
37. Zhan, Q., Carrier, F. and Fornace, A. J., Jr. Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol. Cell. Biol., 13, 4242-4250 (1993).
38. Perry, M. E., Piette, J., Zawadzki, J. A., Harvey, D. and Levine, A. J. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc. Natl. Acad. Sci. USA, 90, 11623-11627 (1993).
39. Lianes, P., Orlow, I., Zhang, Z. F., Oliva, M. R., Sarkis, A. S., Reuter, V. E. and Cordon-Cardo, C. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J. Natl. Cancer Inst., 86, 1325-1330 (1994).
40. Riou, G., Barrois, M., Prost, S., Terrier, M. J., Theodore, C. and Levine, A. J. The p53 and mdm-2 genes in human testicular germ-cell tumors. Mol. Carcinog., 12, 124-131 (1995).
41. Maestro, R., Gloghini, A., Doglioni, C., Gasparotto, D., Vukosavljevic, T., De Re, V., Laurino, L., Carbone, A. and Boiocchi, M. MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas. Blood, 85, 3239-3246 (1995).
42. Landers, J. E., Cassel, S. L. and George, D. L. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res., 57, 3562-3568 (1997).
43. Landers, J. E., Haines, D. S., Strauss, J. F., 3rd and George, D. L. Enhanced translation: a novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene, 9, 2745-2750 (1994).
44. Keleti, J., Quezado, M. M., Abaza, M. M., Raffeld, M. and Tsokos, M. The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am. J. Pathol., 49, 143-151 (1996).
45. Zou, M., Shi, Y., al-Sedairy, S., Hussain, S. S. and Farid, N. R. The expression of the MDM2 gene, a p53 binding protein, in thyroid carcinogenesis. Cancer, 76, 314-318 (1995).
46. Gunther, T., Schneider-Stock, R., Rys, J., Niezabitowski, A. and Roessner, A. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors. J. Cancer Res. Clin. Oncol., 123, 388-394 (1997).
47. Bull, E. K., Chakrabarty, S., Brodsky, I. and Haines, D. S. mdm2-P2 transcript levels predict the functional activity of the p53 tumor suppressor in primary leukemic cells. Oncogene, 16, 2249-2257 (1998).
48. Borden, K. L. and Freemont, P. S. The RING finger domain: a recent example of a sequence-structure family. Curr. Opin. Struct. Biol., 6, 395-401 (1996).
49. Saurin, A. J., Hamlett, J., Clague, M. J. and Pennington, S. R. Inhibition of mitogen-induced DNA synthesis by bafilomycin A1 in Swiss 3T3 fibroblasts. Biochem. J., 313, 65-70 (1996).